Fei F, Abdel-Azim, H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, Heisterkamp N. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 27: 2385-2388, 2013. https://www.nature.com/articles/leu2013175
Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc engineered monoclonal antibody targeting the BAFF-R. Mol. Cancer Ther. 13, 1567-1577, 2014. http://mct.aacrjournals.org/content/13/6/1567.full-text.pdf
Joo EJ, Wasik BR, Parrish C, Paz H, MÏ‹hlenhoff M, Abdel-Azim H, Groffen J, Heisterkamp N. Pre-B acute lymphoblastic leukemia expresses cell surface nucleolin as a 9-O-acetylated sialoglycoprotein. Sci Rep 2018, 8: 17174. https://www.nature.com/articles/s41598-018-33873-2
Fousek K, Watanabe J, Joseph S, George A, An X, Byrd TT, Martínez-Paniagua MA, Sanber K, Navai SA, Gad AZ, Salsman VS, Mathew PR, Kim H-n, Wagner DL, Brunetti L, Jang A, Baker ML, Varadarajan N, Hegde M, Kim Y-m, Heisterkamp N, Abdel-Azim H, Ahmed N. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia, 35, 75-89, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519582/
Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc engineered monoclonal antibody targeting the BAFF-R. Mol. Cancer Ther. 13, 1567-1577, 2014. http://mct.aacrjournals.org/content/13/6/1567.full-text.pdf
Oncoimmunology 1:618-629, 2012.Fei F, Abdel-Azim, H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, Heisterkamp N. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 27: 2385-2388, 2013. https://www.nature.com/articles/leu2013175
Fei F, Lim M, George A, Kirzner J, Lee D, Seeger R, Groffen J, *Abdel-Azim H, *Heisterkamp N. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia, 29, 788-797, 2015. https://www.nature.com/articles/leu2014246
Parameswaran R, Yu M, Lim M, Lyu M-A, Rosenblum, MG, Groffen J, Heisterkamp N. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia 26:1786-1796, 2012. https://www.nature.com/articles/leu201254
Yu M, Jiang E, Parameswaran R, Stoddart S, Fei F, Müschen M, Park E, Hsieh Y-T, Martinelli G, Hofmann W-K, Yang AS, Groffen J, Heisterkamp N, Kim Y-m. AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo. Blood Cancer J. 1:e14, 2011. https://www.nature.com/articles/bcj201113
Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25:1314-1323, 2011. https://pubmed.ncbi.nlm.nih.gov/21483439/
Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber SM, Yi S-J, Kim Y-m, Groffen J, Heisterkamp N. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. https://www.tandfonline.com/doi/abs/10.4161/onci.20249